Publication: Expression of androgen receptor and its regulatory molecule lin28 in non-luminal subtype breast cancer
Issued Date
2020-01-01
Resource Type
ISSN
20499469
20499450
20499450
Other identifier(s)
2-s2.0-85085348674
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecular and Clinical Oncology. Vol.12, No.6 (2020), 511-518
Suggested Citation
Doonyapat Sa-Nguanraksa, Wanee Pongthong, Norasate Samarnthai, Kwanlada Mitpakdi, Tuenjai Chuangsuwanich, Thawornchai Limjindaporn, Anchalee Kulprom, Pornchai O-Charoenrat Expression of androgen receptor and its regulatory molecule lin28 in non-luminal subtype breast cancer. Molecular and Clinical Oncology. Vol.12, No.6 (2020), 511-518. doi:10.3892/mco.2020.2029 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/56132
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Expression of androgen receptor and its regulatory molecule lin28 in non-luminal subtype breast cancer
Other Contributor(s)
Abstract
© 2020, Spandidos Publications. All rights reserved. Androgen receptor (AR) was associated with favourable outcome in luminal breast cancer. However, the role of AR in non-luminal breast cancer remains inconclusive. The aim of the present study was to evaluate the clinical significance of t he AR and its regulator y pat hway in non-luminal subtypes of breast cancer. In total, 284 breast cancer patients were recruited from January 2007 to January 2016. Tissue microarrays were constructed from archival paraffin blocks and assessed for AR and its regulatory molecule, Lin28, by immunohistochemistry. The association between AR and Lin28 expression and clinicopathological parameters was analyzed. Results showed that AR and Lin28 were co-expressed. No association between these proteins and clinicopathological parameters, and survival outcome was found. However, a higher proportion of the patients with AR and Lin28 expression were observed in HER2 subtype. In conclusion, Lin28 may be a novel marker for prognosis and targeted for treatment in HER2 subtype breast cancer.